Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
May 04, 2023 16:05 ET
|
Relay Therapeutics, Inc.
Presented initial clinical data for RLY-2608 at American Association for Cancer Research (AACR) Annual Meeting 2023 Initiated clinical trial for RLY-5836, a chemically-distinct PI3Kα pan-mutant...
Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
April 27, 2023 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
April 19, 2023 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., April 19, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two upcoming fireside chats: Stifel 2023 Targeted Oncology Days, on...
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
April 18, 2023 10:40 ET
|
Relay Therapeutics, Inc.
Multiple doses achieved sustained target exposure of ~80%+ mutant PI3Kα inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at target...
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
March 06, 2023 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
March 01, 2023 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in two fireside chats this month, at the Cowen 43rd Annual Health Care...
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
February 23, 2023 16:05 ET
|
Relay Therapeutics, Inc.
Advanced RLY-4008: Reported interim data with 88% overall response rate at pivotal dose and 63% across all doses in pan-FGFR treatment-naïve, FGFR2-fusion cholangiocarcinoma patients & announced...
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
February 16, 2023 16:05 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...
Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
February 02, 2023 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on...
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 07:30 ET
|
Relay Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining...